Schizophrenia Clinical Trials in DeSoto, Texas

9 studies are recruiting for schizophrenia in DeSoto, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Effect of KarXT on Urological Safety

   The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Adams Clinical Dallas, DeSoto, Texas

   Locations

   16 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07221877 on ClinicalTrials.gov

2. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, DeSoto, Texas

   Locations

   45 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

3. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Adams Clinical Dallas, DeSoto, Texas

   Locations

   101 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

4. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

   This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, DeSoto, Texas

   Locations

   61 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07114874 on ClinicalTrials.gov

5. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

   The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, DeSoto, Texas

   Locations

   25 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07227818 on ClinicalTrials.gov

6. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Adams Clinical, DeSoto, Texas

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

7. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Alkermes Investigator Site, DeSoto, Texas

   Locations

   47 in total

   Run by

   Alkermes, Inc.

   See if you can join NCT05303064 on ClinicalTrials.gov

8. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

   This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

   Stage

   Phase 1

   Ages

   10 to 17

   Site

   BioXcel Clinical Research Site, DeSoto, Texas

   Locations

   5 in total

   Run by

   BioXcel Therapeutics Inc

   See if you can join NCT05025605 on ClinicalTrials.gov

9. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

   The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, DeSoto, Texas

   Locations

   21 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06963034 on ClinicalTrials.gov